We look forward to attending the BIO International Convention this year in Boston. For a second year we are proud to be attending as part of the UK Pavilion, and we look forward to showcasing our specialty services as a full service CRO.
Please do visit our booth at the UK Pavilion, booth 765 and chat with Mo and Rich to learn more about hVIVO and how we can help you with your clinical trial.
As the global leader in human challenge trials, hVIVO has a long and unique history in the field of clinical trials. Having now moved to the new facility in the UK’s life science quarter in London’s Canary Wharf, we have expanded the services we offer with not only a standalone specialist virology and immunology laboratory, with BSL 2 and BSL 3 facilities, hLAB but a dedicated outpatient unit for Phase II and Phase III trials.
At the beginning of 2025 we added to the Group with the acquisition of CRS Early Phase and along with our existing consulting arm, Venn Life Sciences we offer end-to-end services from discovery through drug development and lifecycle management. CRS Early Phase, focuses on Phase I and Phase II studies whilst Venn Life Science’s expertise covers the drug development pathway, with SME’s in CMC, non-clinical, clinical as well as regulatory affairs, biostatistics and study design.
At hVIVO we have been studying Influenza for over 20 years and running human challenge studies with our flu disease models for over 15 years. We have delivered flu challenge studies for industry, governmental and academic partners, making our tool the most well-used commercial flu disease models available on the market. As well as our established influenza A model, we have developed the first Influenza B challenge model, you can find out more about this on our Influenza model page.
We are currently in the final stages of a characterisation study on our latest model, for hMPV, further expanding the dataset and building on our pilot study from late 2024 with our goal to commence human challenge trials in the second half of 2025. You can read more about our hMPV challenge model here and find out more about the pilot study data by watching Dr Andrew Catchpole present the headline data here.
As the global leader in human challenge trials, hVIVO has vast experience investigating RSV infection, having inoculated almost 2000 participants with RSV, hVIVO has the only commercially available RSV challenge model, which has been a part of the accelerated development of a number of vaccines/antivirals in avoiding the risks and pitfalls of expensive large-scale Phase II and Phase III studies.
We also have a Covid-19 challenge model that offers drug and vaccine developers a wide range of solutions to speed up the development of their product. Using human challenge studies allows us to move past the unpredictability of future Covid-19 outbreaks, and quickly and efficiently obtain efficacy data.
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
